MDT

100.05

+3%↑

A

146.51

+3.24%↑

VEEV

236.48

+6.28%↑

HQY

95.71

+1.86%↑

PHR.US

17.15

+0.06%↑

MDT

100.05

+3%↑

A

146.51

+3.24%↑

VEEV

236.48

+6.28%↑

HQY

95.71

+1.86%↑

PHR.US

17.15

+0.06%↑

MDT

100.05

+3%↑

A

146.51

+3.24%↑

VEEV

236.48

+6.28%↑

HQY

95.71

+1.86%↑

PHR.US

17.15

+0.06%↑

MDT

100.05

+3%↑

A

146.51

+3.24%↑

VEEV

236.48

+6.28%↑

HQY

95.71

+1.86%↑

PHR.US

17.15

+0.06%↑

MDT

100.05

+3%↑

A

146.51

+3.24%↑

VEEV

236.48

+6.28%↑

HQY

95.71

+1.86%↑

PHR.US

17.15

+0.06%↑

Search

Ligand Pharmaceuticals Inc

Avatud

SektorTervishoid

189.64 0.82

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

188.97

Max

193.4

Põhinäitajad

By Trading Economics

Sissetulek

112M

117M

Müük

115M

P/E

Sektori keskmine

86.354

88.032

Kasumimarginaal

101.569

Töötajad

68

EBITDA

87M

149M

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+28.08% upside

Turustatistika

By TradingEconomics

Turukapital

-278M

3.8B

Eelmine avamishind

188.82

Eelmine sulgemishind

189.64

Uudiste sentiment

By Acuity

21%

79%

39 / 374 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Strong Bearish Evidence

Ligand Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

5. jaan 2026, 18:06 UTC

Suurimad hinnamuutused turgudel

LifeMD Shares Rise After Company Offers Novo Nordisk's Wegovy

5. jaan 2026, 23:51 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. jaan 2026, 23:51 UTC

Market Talk

Global Equities Roundup: Market Talk

5. jaan 2026, 23:51 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

5. jaan 2026, 23:42 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Lower on Likely Technical Correction -- Market Talk

5. jaan 2026, 21:52 UTC

Uudisväärsed sündmused

Oil Stocks, Banks Push Dow to New Record -- WSJ

5. jaan 2026, 21:51 UTC

Uudisväärsed sündmused

Palantir Stock Jumps. How It Benefited from the Venezuela Raid. -- Barrons.com

5. jaan 2026, 21:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5. jaan 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

5. jaan 2026, 21:38 UTC

Uudisväärsed sündmused

Stock Market Today: Dow Jumps to Record After U.S. Captures Venezuela's Maduro -- WSJ

5. jaan 2026, 21:09 UTC

Omandamised, ülevõtmised, äriostud

SGH, Steel Dynamics Won't Need to Raise Equity to Fund Transaction

5. jaan 2026, 21:09 UTC

Omandamised, ülevõtmised, äriostud

SGH, Steel Dynamics to Fund Transaction With Cash, Available Debt Financing

5. jaan 2026, 21:08 UTC

Omandamised, ülevõtmised, äriostud

SGH Proposes Minimum One Board Position for BlueScope Directors to Maintain Continuity

5. jaan 2026, 21:06 UTC

Omandamised, ülevõtmised, äriostud

SGH, Steel Dynamics Offer Values BlueScope's Equity at A$13.2 Billion

5. jaan 2026, 21:06 UTC

Omandamised, ülevõtmised, äriostud

SGH Would Retain Remainder of BlueScope's Operations if Deal Completes

5. jaan 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

SGH Would Sell BlueScope's North American Operations to Steel Dynamics if Deal Completes

5. jaan 2026, 21:05 UTC

Omandamised, ülevõtmised, äriostud

SGH, Steel Dynamics Offering A$30.00/Share in Cash to Acquire BlueScope

5. jaan 2026, 21:04 UTC

Omandamised, ülevõtmised, äriostud

SGH, Steel Dynamics Make Takeover Offer for BlueScope Steel

5. jaan 2026, 20:18 UTC

Market Talk

U.S. Natural Gas Extends Losses on Milder Weather Outlook -- Market Talk

5. jaan 2026, 20:08 UTC

Market Talk

Venezuela Needs Billions in Investment for Oil-Production Growth -- Market Talk

5. jaan 2026, 19:16 UTC

Market Talk
Uudisväärsed sündmused

Alberta Says Canada Needs to Expedite Pipeline Projects Following Trump's Venezuela Move -- Market Talk

5. jaan 2026, 18:57 UTC

Market Talk
Uudisväärsed sündmused

Quick Return of Venezuelan Oil Barrels A Possibility -- Market Talk

5. jaan 2026, 18:23 UTC

Market Talk

Moody's Should See Boost from Strong Debt Issuance Year -- Market Talk

5. jaan 2026, 18:08 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5. jaan 2026, 18:08 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

5. jaan 2026, 18:08 UTC

Market Talk
Uudisväärsed sündmused

Canadian Heavy Oil Producers at Risk From a Revitalized Venezuela -- Market Talk

5. jaan 2026, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

5. jaan 2026, 17:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5. jaan 2026, 17:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

5. jaan 2026, 17:08 UTC

Tulu

Strategy Records $17.44 Billion Unrealized Loss in Fourth Quarter -- WSJ

Võrdlus sarnastega

Hinnamuutus

Ligand Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

28.08% tõus

12 kuu keskmine prognoos

Keskmine 243.5 USD  28.08%

Kõrge 275 USD

Madal 220 USD

Põhineb 7 Wall Streeti analüütiku instrumendi Ligand Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

7 ratings

7

Osta

0

Hoia

0

Müü

Tehniline skoor

By Trading Central

102.5 / 109.24Toetus ja vastupanu

Lühikene perspektiiv

Strong Bearish Evidence

Keskpikk perspektiiv

Very Strong Bearish Evidence

Pikk perspektiiv

Weak Bullish Evidence

Sentiment

By Acuity

39 / 374 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Ligand Pharmaceuticals Inc

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, engages in the development and licensing of biopharmaceutical assets worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; Filspari, a dual endothelin and angiotensin II receptor antagonist in development for rare kidney diseases and non-immunosuppressive treatment indicated for immunoglobulin A nephropathy; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by streptococcus pneumoniae serotypes; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers TZIELD, a CD3-directed antibody indicated to delay the onset of Stage 3 type 1 diabetes (T1D) in adults and children aged 8 years and older with Stage 2 T1D; Nexterone, a captisol-enabled formulation of amiodarone; Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression; and Veklury, an antiviral treatment for moderate or severe COVID-19. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of post-menopausal symptoms in women; Exemptia for autoimmune diseases; Vivitra for breast cancer; and Bryxta and Zybev for various indications. The company has alliances, licenses, and other business relationships with Amgen, Merck, Pfizer, Jazz, Takeda, Gilead Sciences, and Baxter International. Further, it sells Captisol materials. Ligand Pharmaceuticals Incorporated was incorporated in 1987 and is based in Jupiter, Florida.
help-icon Live chat